1 research outputs found
Π ΠΎΠ»Ρ ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Ρ ΠΏΠΎΠ΄ΡΠ΅ΠΌΠΎΠΌ ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST: ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ ΠΈ ΠΌΠ΅ΡΠ°Π°Π½Π°Π»ΠΈΠ·
Background: There have been a big number of studies assessing the efficacy of delayed coronary artery stenting (DCAS) in the prevention of no-reflow microvasculature injury compared to the standard immediate coronary artery stenting (ICAS) in ST-segment elevation myocardial infarction (STEMI). However, the results of these studies are contradictory in a lot of ways.
Aim: To summarize studies on the assessment of DCAS in the prevention of no-reflow compared to the standard ICAS.
Materials and methods: We performed a systematic literature search in PubMed, Google Scholar, and eLIBRARY.RU databases. The analysis included 17 studies with a total sample of 3505 patients. The comparative analysis included angiography-based endpoints prevalence of no-reflow (thrombolysis in myocardial infarction, TIMI 3 and myocardial blush grade, MBG 2, corrected TIMI frame count, CTFC) and clinical endpoints of all-cause mortality, cardiovascular mortality, major adverse cardiac events (MACE), recurrent myocardial infarction and recurrent revascularization. In addition, the analysis included the assessment of ST-elevation resolution, left ventricular ejection fraction values in the delayed post-intervention period and between-group differences.
Results: The no-reflow phenomenon was significantly less frequent in the DCAS groups for the following parameters: epicardial flow TIMI 3 (odds ratio (OR) 2.00; 95% confidence interval (CI) 1.492.69; p 0.00001; I = 16%), myocardial perfusion MBG 2 (OR 4.69; 95% CI 1.9811.14; p = 0.0005; I = 59%), CTFC (mean difference (MD) 10.29; 95% CI 0.9619.62; p = 0.03; I = 96%). The analysis of secondary endpoints showed that MACE were less frequent in the DCAS groups (OR 1.29; 95% CI 1.041.60; p = 0.02; I = 42%), the difference becoming more significant in the studies with high initial thrombotic burden (TTG 3) (OR 1.83; 95% CI 1.282.62; p = 0.0009; I = 41%). The most clinically significant decrease of the MACE rate was found in 5 studies (n = 656) with high initial thrombotic burden (TTG 3) and mean time to repeated intervention from 4 to 7 days (OR 3.15; 95% CI 1.865.32; p 0.0001; I = 0%). The reverse trend for a benefit in the ICAS group was observed in the studies with a high initial thrombotic burden (TTG 3) and mean time to recurrent intervention of 48 hours (OR 0.60; 95% CI 0.301.19; p = 0.14; I = 20%). The ICAS and DCAS groups did not differ in overall mortality (p = 0.31), cardiovascular mortality (p = 0.49), repeated revascularization (p = 0.66), and ST resolution of 70% (p = 0.65). In the DCAS groups, there was an obvious trend to lower incidence of recurrent myocardial infarction (OR 1.28; 95% CI 0.951.73; p = 0.10; I = 0%), as well as to higher myocardial mass during the deferred analysis of left ventricular ejection fraction (OR -0.79; 95% CI -1.61 -0.04; p = 0.06; I = 36%).
Conclusion: Deferred coronary artery stenting is an effective method for prevention of no-reflow. In patients with extended coronary thrombosis (TTG 3) and STEMI, the DCAS technique with time to recurrent intervention of 4 to 7 days decreases the probability of MACE compared to that with immediate stenting of the index coronary artery.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½ΠΎ Π±ΠΎΠ»ΡΡΠΎΠ΅ ΡΠΈΡΠ»ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π² ΠΊΠΎΡΠΎΡΡΡ
ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
Π°ΡΡΠ΅ΡΠΈΠΉ (ΠΠ‘ΠΠ) Π² ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΌΠΈΠΊΡΠΎΡΠΈΡΠΊΡΠ»ΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ»Π° (no-reflow) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠΌ Π½Π΅ΠΌΠ΅Π΄Π»Π΅Π½Π½ΡΠΌ ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
Π°ΡΡΠ΅ΡΠΈΠΉ (ΠΠ‘ΠΠ) ΠΏΡΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Ρ ΠΏΠΎΠ΄ΡΠ΅ΠΌΠΎΠΌ ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST. ΠΠ΄Π½Π°ΠΊΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π²ΠΎ ΠΌΠ½ΠΎΠ³ΠΎΠΌ ΠΏΡΠΎΡΠΈΠ²ΠΎΡΠ΅ΡΠ°Ρ Π΄ΡΡΠ³ Π΄ΡΡΠ³Ρ.
Π¦Π΅Π»Ρ ΠΎΠ±ΡΠ΅Π΄ΠΈΠ½ΠΈΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΠΠ‘ΠΠ Π² ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ΅ no-reflow ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΠ‘ΠΠ.
ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΏΠΎΠ»Π½Π΅Π½ ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΠΎΠΈΡΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ Π² Π±Π°Π·Π°Ρ
Π΄Π°Π½Π½ΡΡ
PubMed, Google Scholar, eLIBRARY.RU. Π Π°Π½Π°Π»ΠΈΠ· Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 17 ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Ρ ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠ±ΠΎΡΠΊΠΎΠΉ Π² 3505 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π°Π½Π³ΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠΎΠ½Π΅ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ no-reflow ( 3 Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ ΡΠΊΠ°Π»Π΅ TIMI (Π°Π½Π³Π». Thrombolysis In Myocardial Infarction) ΠΈ 2 Π±Π°Π»Π»ΠΎΠ² ΠΏΠΎ ΡΠΊΠ°Π»Π΅ MBG (Π°Π½Π³Π». Myocardial Blush Grade), ΡΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π°Π½ΡΠ΅Π³ΡΠ°Π΄Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΡΠΎΠΊΠ° ΠΏΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Ρ ΠΊΠ°Π΄ΡΠΎΠ² (Π°Π½Π³Π». Ρorrected TIMI frame count, CFTC), Π°Π½Π°Π»ΠΈΠ· ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠΎΠ½Π΅ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ, ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ, Π±ΠΎΠ»ΡΡΠΈΡ
ΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ (Π°Π½Π³Π». major adverse cardiac events, MACE), ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠ°ΡΠΊΡΠ°, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠΉ ΡΠ΅Π²Π°ΡΠΊΡΠ»ΡΡΠΈΠ·Π°ΡΠΈΠΈ. Π Π°Π½Π°Π»ΠΈΠ· ΡΠ°ΠΊΠΆΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΡΠ΅Π·ΠΎΠ»ΡΡΠΈΠΈ ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST, Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΡΠ°ΠΊΡΠΈΠΈ Π²ΡΠ±ΡΠΎΡΠ° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° Π² ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ Π°Π½Π³ΠΈΠΎΠ³ΡΠ°ΡΠΈΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ ΡΠ΅ΠΆΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΡΡΡ no-reflow: ΠΏΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΡΠΏΠΈΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΡΠΎΠΊΠ° TIMI 3 (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π½ΡΠΎΠ² (ΠΠ¨) 2,00; 95% Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» (ΠΠ) 1,492,69; p 0,00001; I = 16%), ΠΏΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ΅ΡΡΡΠ·ΠΈΠΈ MBG 2 (ΠΠ¨ 4,69; 95% ΠΠ 1,9811,14; p = 0,0005; I = 59%), ΠΏΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ CFTC (ΡΡΠ΅Π΄Π½ΡΡ ΡΠ°Π·Π½ΠΎΡΡΡ (Π‘Π ) 10,29; 95% ΠΠ 0,9619,62; p = 0,03; I = 96%). ΠΠ½Π°Π»ΠΈΠ· Π²ΡΠΎΡΠΈΡΠ½ΡΡ
ΠΊΠΎΠ½Π΅ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ ΠΏΠΎΠΊΠ°Π·Π°Π»: MACE ΡΠ΅ΠΆΠ΅ Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΠΠ‘ΠΠ (ΠΠ¨ 1,29; 95% ΠΠ 1,041,60; p = 0,02; I = 42%), ΡΡΠΎ ΡΡΠ°Π½ΠΎΠ²ΠΈΡΡΡ Π±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΏΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΈΠ·Π½Π°ΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΎΠΉ (TTG 3) (ΠΠ¨ 1,83; 95% ΠΠ 1,282,62; p = 0,0009; I = 41%). ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ MACE ΠΎΡΠΌΠ΅ΡΠ΅Π½ Π² 5 ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
(n = 656) c Π²ΡΡΠΎΠΊΠΎΠΉ ΠΈΠ·Π½Π°ΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΎΠΉ (TTG 3) ΠΈ ΡΡΠ΅Π΄Π½ΠΈΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΎΠΌ Π΄ΠΎ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π° ΠΎΡ 4 Π΄ΠΎ 7 Π΄Π½Π΅ΠΉ (ΠΠ¨ 3,15; 95% ΠΠ 1,865,32; p 0,0001; I = 0%). ΠΠ±ΡΠ°ΡΠ½ΡΡ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²ΠΎ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΠ‘ΠΠ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΈ ΠΏΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ c Π²ΡΡΠΎΠΊΠΎΠΉ ΠΈΠ·Π½Π°ΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠΎΠΉ (TTG 3) ΠΈ ΡΡΠ΅Π΄Π½ΠΈΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΎΠΌ Π΄ΠΎ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π° 48 ΡΠ°ΡΠΎΠ² ΠΈΠ»ΠΈ ΠΌΠ΅Π½ΡΡΠ΅ (ΠΠ¨ 0,60; 95% ΠΠ 0,301,19; p = 0,14; I = 20%). ΠΡΠΈ ΡΡΠΎΠΌ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ ΠΠ‘ΠΠ ΠΈ ΠΠ‘ΠΠ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠΉ ΡΠ°Π·Π½ΠΈΡΡ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ ΠΎΠ±ΡΠ΅ΠΉ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ (p = 0,31), ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ (p = 0,49), Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠΉ ΡΠ΅Π²Π°ΡΠΊΡΠ»ΡΡΠΈΠ·Π°ΡΠΈΠΈ (p = 0,66), ΡΠ΅Π·ΠΎΠ»ΡΡΠΈΠΈ ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST 70% (p = 0,65). Π Π³ΡΡΠΏΠΏΠ°Ρ
ΠΠ‘ΠΠ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Π²ΡΡΠ°ΠΆΠ΅Π½Π½Π°Ρ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° (ΠΠ¨ 1,28; 95% ΠΠ 0,951,73; p = 0,10; I = 0%), Π° ΡΠ°ΠΊΠΆΠ΅ ΠΊ ΡΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ Π±ΠΎΠ»ΡΡΠ΅ΠΉ ΠΌΠ°ΡΡΡ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΏΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ΡΡΠ°ΠΊΡΠΈΠΈ Π²ΡΠ±ΡΠΎΡΠ° Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° Π² ΠΎΡΡΡΠΎΡΠ΅Π½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ (Π‘Π -0,79; 95% ΠΠ -1,61 -0,04; p = 0,06; I = 36%).
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΡΡΠΎΡΠ΅Π½Π½ΠΎΠ΅ ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ
Π°ΡΡΠ΅ΡΠΈΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ no-reflow. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΠΌ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠΌ (TTG 3) ΠΏΡΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Ρ ΠΏΠΎΠ΄ΡΠ΅ΠΌΠΎΠΌ ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ΠΠ‘ΠΠ Ρ ΠΏΠ΅ΡΠΈΠΎΠ΄ΠΎΠΌ Π΄ΠΎ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π° Π² 47 Π΄Π½Π΅ΠΉ ΡΠ½ΠΈΠΆΠ°Π΅Ρ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ MACE ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π½Π΅ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ½ΡΠ°ΡΠΊΡ-ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ